Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) Added to Fludarabine, Bendamustine and Rituximab and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 25 Jul 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Inotuzumab ozogamicin (Primary) ; Antithymocyte globulin; Bendamustine; Filgrastim; Fludarabine; Methotrexate; Rituximab; Tacrolimus; Tacrolimus
Indications B-cell leukaemia; B-cell lymphoma
Focus Adverse reactions

29 Apr 2024 Results of safety and long-term survival , published in the American Journal of Hematology
20 Jul 2023 Status changed from active, no longer recruiting to completed.
30 Jun 2023 Planned End Date changed from 30 Jun 2023 to 30 Sep 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com